This graphing tool allows users to explore trends in workplace-sponsored health insurance premiums and worker contributions over time for different categories of employers based on results from the annual Employer Health Benefits Survey. Breakouts are…
This annual survey of employers provides a detailed look at trends in employer-sponsored health coverage, including premiums, worker contributions, cost-sharing provisions, offer rates, and more. This year’s report also looks at how employers are addre…
KFF has conducted this annual survey since 1999.
Amid rising inflation, annual family premiums for employer-sponsored health insurance climbed 7% on average this year to reach $23,968, a sharp departure from virtually no growth in premiums last year, the 2023 benchmark KFF Employer Health Benefits Su…
The analysis finds that life expectancy in the U.S. fell by 2.7 years from 2019 to 2021, whereas in peer countries’ life expectancies fell by an average of just 0.2 years in this period. COVID-19 has erased two decades of life expectancy growth in the …
This chart collection explores how health spending is expected to grow in coming years, with a look at growth in prescription drug spending, out-of-pocket spending, and related trends.
KFF Health News won the 2023 Loeb Award in the personal finance and consumer reporting category for its in-depth coverage of consumer medical debt in its “Diagnosis: Debt” series. In partnership with NPR and CBS News, KFF Health News examined the stori…
This Data Note includes major findings from the KFF Consumer Survey on consumer experiences with claim denials. Among those who used the most health care over the past year, 27% experienced a denied claim. More consumers with private insurance experie…
This analysis of 2021 claims data finds that while telehealth use remained high in the second year of the COVID-19 pandemic, the shift toward virtual physician and mental health care did not materially affect how much insurers paid for each patient enc…
This brief examines how Part D enrollees’ access to and utilization of the first set of 10 selected drugs could be affected by the new Part D coverage and formulary requirements for selected drugs established by the Inflation Reduction Act and in CMS g…
